Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 19, 2018

Study Completion Date

February 21, 2019

Conditions
Malaria
Interventions
BIOLOGICAL

PRIMVAC

3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)

BIOLOGICAL

GLA-SE

2.56 µg of GLA content

BIOLOGICAL

Alhydrogel

0.85 mg og Aluminium content

BIOLOGICAL

Placebo

0.9% Na cl

Trial Locations (2)

75679

CIC 1417, Paris

BP 2208

CNRFP, Ouagadougou

Sponsors
All Listed Sponsors
collaborator

European Vaccine Initiative

OTHER

collaborator

Recherche Clinique Paris Descartes Necker Cochin Sainte Anne

OTHER

collaborator

Centre national de recherche et de formation sur le paludisme

OTHER_GOV

collaborator

EUCLID Clinical Trial Platform

OTHER

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02658253 - Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults | Biotech Hunter | Biotech Hunter